Evidence map›Paper›PMID 42651704›Full record

ReviewBiology2026

Reimagining Spinal Surgery at the Nanoscale: Smart Implants, Targeted Therapies, and Translational Challenges.

Alexander Shao-Rong Pang, Kimberley Yun-Lin Pang, Zi Qiang Glen Liau, Arun-Kumar Kaliya-Perumal, Jacob Yoong-Leong Oh, Dinesh Kumar Srinivasan

Abstract readReview
In one paragraph

Review in Biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Alexander Shao-Rong PangYong Loo Lin School of Medicine, National University of Singapore, Singapore 117597, Singapore.ORCID 0009-0003-3195-5491
Kimberley Yun-Lin PangDepartment of Orthopaedic Surgery, Tan Tock Seng Hospital, Singapore 308433, Singapore.
Zi Qiang Glen LiauDepartment of Orthopaedic Surgery, National University Hospital, Singapore 119074, Singapore.ORCID 0000-0002-0498-9237
Arun-Kumar Kaliya-PerumalRehabilitation Research Institute of Singapore, Nanyang Technological University, Singapore 308232, Singapore.ORCID 0000-0002-2747-4500
Jacob Yoong-Leong OhDepartment of Orthopaedic Surgery, Tan Tock Seng Hospital, Singapore 308433, Singapore.
Dinesh Kumar SrinivasanDepartment of Anatomy, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117594, Singapore.ORCID 0000-0001-6535-5441

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Spinal pathologies, including degenerative disc disease, spinal cord injury, and conditions requiring spinal fusion, pose a substantial global health burden. While contemporary interventions provide symptomatic relief, achieving durable tissue repair in biologically compromised environments remains a critical challenge. This narrative review synthesizes the current literature on three major nanotechnology applications in spine care: nanostructured implant surfaces, nanoparticle-enhanced bone grafts, and nano-drug delivery systems (NDDSs). Preclinical evidence indicates that nanoscale surface modifications and nanoparticle-augmented synthetic grafts significantly enhance osseointegration and bone fusion by mimicking the native extracellular matrix. Furthermore, in animal models of intervertebral disc degeneration, NDDSs utilizing polymeric nanoparticles and exosomes facilitate sustained, stimuli-responsive therapeutic delivery into the avascular disc space. Although early clinical data on nanostructured cages demonstrate reduced subsidence and stable long-term fusion, the direct translation of these robust preclinical outcomes to widespread clinical efficacy faces substantial hurdles. Significant translational barriers include stringent Class III regulatory classifications, sparse long-term safety data regarding nanoparticle biodistribution, and scale-up manufacturing challenges such as batch variability. Future progress relies on artificial intelligence-guided design, three-dimensional (3D) bioprinting, and multifunctional "smart" nanomaterials. Ultimately, close collaboration among materials scientists, clinicians, and regulatory bodies is essential to safely bridge the gap between preclinical innovation and predictable clinical therapeutic success.

Indexed as

intervertebral disc degenerationnano-drug delivery systemsnanostructured implant surfacesnanotechnologyosseointegration

Identifiers

PMID42651704
PMCPMC13510190

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.